Widely used:Recently Viewed
Clear All
Today’s Range
52 Week Range
Liquidity
Market cap
$6,145 Mln
P/E Ratio
--
P/B Ratio
5.95
Industry P/E
--
Debt to Equity
0.34
ROE
-0.15 %
ROCE
-11.92 %
Div. Yield
0 %
Book Value
--
EPS
--
CFO
$-783.72 Mln
EBITDA
$-1,674.51 Mln
Net Profit
$-1,780.68 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Legend Biotech Corp (LEGN)
| 0.80 | -11.83 | 4.36 | -34.56 | -6.89 | -- | -- |
|
BSE Sensex
| 0.39 | 6.40 | 1.96 | 7.69 | 10.43 | 20.75 | 10.61 |
|
2024
|
2023
|
2022
|
2021
|
|
|---|---|---|---|---|
|
Legend Biotech Corp (LEGN)
| -45.65 | 20.53 | 7.10 | 65.52 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 36.19 | 10,117.70 | 20.54 | 23.13 | |
| 296.28 | 8,962.72 | 23.48 | 58.42 | |
| 24.72 | 9,739.03 | -- | -28.77 | |
| 101.38 | 9,903.71 | 30.43 | 14.16 |
Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe.... Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma (NHL), acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. In addition, it develops allogeneic gamma delta CAR-T and allogeneic CAR-NK product candidates targeting B-cell maturation antigen (BCMA) for MM, which are in investigator-initiated Phase 1 clinical trials in China. The company has a collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of cilta-cel, as well as a license agreement with Novartis Pharma AG for the development, manufacture, and commercialization of CAR-T cell therapies targeting delta-like ligand protein 3. The company was founded in 2014 and is headquartered in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation. Address: 2101 Cottontail Lane, Somerset, NJ, United States, 08873 Read more
CEO & Director
Dr. Ying Huang Ph.D.
CEO & Director
Dr. Ying Huang Ph.D.
Headquarters
Somerset, NJ
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Legend Biotech Corp (LEGN) stood at $ 1,670 Mln as on 31-Dec-24
The share price of Legend Biotech Corp (LEGN) is $32.80 (NASDAQ) as of 17-Apr-2025 16:00 EDT. Legend Biotech Corp (LEGN) has given a return of -6.89% in the last 3 years.
Legend Biotech Corp (LEGN) has a market capitalisation of $ 6,145 Mln as on 17-Apr-2025. As per Value Research classification, it is a company.
Since, TTM earnings of Legend Biotech Corp (LEGN) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Legend Biotech Corp (LEGN) and enter the required number of quantities and click on buy to purchase the shares of Legend Biotech Corp (LEGN).
Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma (NHL), acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. In addition, it develops allogeneic gamma delta CAR-T and allogeneic CAR-NK product candidates targeting B-cell maturation antigen (BCMA) for MM, which are in investigator-initiated Phase 1 clinical trials in China. The company has a collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of cilta-cel, as well as a license agreement with Novartis Pharma AG for the development, manufacture, and commercialization of CAR-T cell therapies targeting delta-like ligand protein 3. The company was founded in 2014 and is headquartered in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation. Address: 2101 Cottontail Lane, Somerset, NJ, United States, 08873
The CEO & director of Dr. Ying Huang Ph.D.. is Legend Biotech Corp (LEGN), and CFO & Sr. VP is Dr. Ying Huang Ph.D..
There is no promoter pledging in Legend Biotech Corp (LEGN).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,012
|
|
|
990
|
|
|
974
|
|
|
896
|
| Legend Biotech Corp (LEGN) | Ratios |
|---|---|
|
Return on equity(%)
|
-15.45
|
|
Operating margin(%)
|
-21.76
|
|
Net Margin(%)
|
-28.22
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Legend Biotech Corp (LEGN) was $0 Mln.
$-0.66
(
